Article metrics

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study


Online download statistics by month:

Online download statistics by month: May 2022 to February 2023

May 202214714922
Jun 202213161342438
Jul 2022820840239
Aug 2022465481138
Sep 2022458463104
Oct 202225926375
Nov 202213714141
Dec 202218017954
Jan 202318117669
Feb 202331431265